ASTRAZENECA (ZEG.SG) (ZEG STU) stock market data APIs
€174.3157
-2.72(-1.6%)
as of April 2, 2026
Try our APIs with
free plan!
ASTRAZENECA (ZEG.SG) Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for ZEG.SG.
Prev. Close
174.3157
Open
171.5955
High
175.1011
Low
170.8649
52 wk Range
108.1053-179.0189
Market Cap
148 612 M
Dividends (Yield)
0.0087
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ASTRAZENECA (ZEG.SG) data using free add-ons & libraries
Get ASTRAZENECA (ZEG.SG) Fundamental Data
ASTRAZENECA (ZEG.SG) Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ASTRAZENECA (ZEG.SG) News
New
AstraZeneca (LSE:AZN) and Daiichi Sankyo's ENHERTU Shows Promising Results in HER2 Breast Cancer Trial
AstraZeneca recently reported a 1.9% decline in its share price over the last week. This movement coincides with the broader market's downturn, which saw a 1.1% drop amid ongoing concerns about intern...
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s ENHERTU isthe first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient ...
Lilly Soars After Weight-Loss Pill Results Rival Ozempic’s
(Bloomberg) -- Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative...
AstraZeneca (LSE:AZN) Gains EU Approval For Breast Cancer Treatment DATROWAY
AstraZeneca saw its share price decline by 3.5% in the last quarter, a period marked by several key developments, including the European approval of DATROWAY for breast cancer treatment and Imfinzi in...
Get ASTRAZENECA (ZEG.SG) fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
